Research and Markets (http://www.researchandmarkets.com/research/mfx9cr/global) has announced the addition of the "2013 Report on the International Cardiovascular Drugs Market - Forecasts to 2016" report to their offering.

In the last few years, the Healthcare industry has witnessed phenomenal growth in the APAC region. Emerging economies such as the APAC region, Eastern Europe, and Latin America hold vast growth potential. These regions are under-equipped to address the increase in the incidence of CVDs in the region. However, the increase in the incidence of CVDs and instances of patients frequently enduring long waits for therapeutic treatments are forcing healthcare organizations in the region to opt for cardiovascular drugs.

Moreover, there has been substantial investment to initiate a significant number of projects in R&D across the developing countries. Hence, healthcare organizations in developing regions such as the APAC region and the Middle East are opting for cardiovascular drugs in accordance with the demand in specific countries. The increasing demand for cardiovascular drugs in the developing countries is boosting the growth of the Global Cardiovascular Drugs market.

One of the major growth factors driving the Global Cardiovascular Drugs market is the increase in the prevalence of cardiovascular patients worldwide. Therapeutic drugs are among the remedies for CVDs, and hence healthcare organizations are opting for cardiovascular drugs for treatments.

Key Topics Covered:

1. Executive Summary

2. Introduction

3. Market Coverage

4. Market Landscape

5. Global Anti-hypertensive Drugs Market

6. Best Selling Anti-hypertensive Drugs

7. Global Anti-dyslipidemics Drugs Market

8. Best Selling Anti-dyslipidemic Drugs

9. Global Anti-thrombotics Drugs Market

10. Best Selling Anti-thrombotic Drugs

11. Drug Pipeline Analysis

12. Geographical Segmentation

13. Key Leading Countries

14. Rate of Incidence and Prevalence

15. Vendor Landscape

16. Buying Criteria

17. Market Challenges

18. Market Growth Drivers

19. Drivers and their Impact

20. Impact of Drivers and Challenges

21. Market Trends

22. Key Vendor Analysis

23. Other Reports in this Series

Companies Mentioned:

  • Abbott Laboratories
  • AstraZeneca
  • Bayer
  • Bristol-Myers Squibb
  • Daiichi Sankyo
  • F. Hoffmann-La Roche
  • Forest Laboratories
  • GlaxoSmithKline
  • Merck & Co
  • Novartis
  • Pfizer
  • Sanofi.
  • Solvay SA
  • Takeda Pharmaceutical
  • The Medicines

For more information visit http://www.researchandmarkets.com/research/mfx9cr/global

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Cardiovascular Devices